Search results
Showing 1096 to 1110 of 1254 results for criteria
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection
Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)
Evidence-based recommendations on darvadstrocel (Alofisel) for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn’s disease.
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on zolbetuximab (Vyloy) with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma in adults.
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
The PediGuard for placing pedicle screws in spinal surgery (MIB26)
NICE has developed a medtech innovation briefing (MIB) on the PediGuard for placing pedicle screws in spinal surgery
Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest (MIB112)
NICE has developed a medtech innovation briefing (MIB) on Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest .
NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .
This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
MRI fusion biopsy systems for diagnosing prostate cancer (HTG678)
Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer.
This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS209Show all sections
Sections for QS209
- Quality statements
- Quality statement 1: Preventing type 2 diabetes
- Quality statement 2: Structured education programme
- Quality statement 3: Continuous glucose monitoring for adults on multiple daily insulin injections who cannot self-monitor using capillary blood glucose monitoring
- Quality statement 4: Continuous glucose monitoring for adults who use insulin and need help monitoring their blood glucose
- Quality statement 5: Treatment with an SGLT-2 inhibitor
- Quality statement 6: 9 key care processes
- Quality statement 7: Assessing the risk of diabetic foot problems on admission to hospital
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.